Posted by cemerman on 10th of Jul 2010 at 01:58 pm
Of course with a biopharmaceutical it is very dependent on it's
drug development milestones. It jumped up in the spring on news of
their colorectal registration trial of perifosine and then on news
that they were accepted for abstract presentation as ASCO. It has
drifted down since then. It might be a good long term play but
these companies can drift for months until they complete trials,
present abstracts, or get FDA review.
Newsletter
Subscribe to our email list for regular free market updates
as well as a chance to get coupons!
Of course with a biopharmaceutical
KERX trade idea
Posted by cemerman on 10th of Jul 2010 at 01:58 pm
Of course with a biopharmaceutical it is very dependent on it's drug development milestones. It jumped up in the spring on news of their colorectal registration trial of perifosine and then on news that they were accepted for abstract presentation as ASCO. It has drifted down since then. It might be a good long term play but these companies can drift for months until they complete trials, present abstracts, or get FDA review.